This new research, published in the Genes & Diseases journal by a team from Chongqing Medical University and Southwest Medical University, investigated the precise mechanisms by which the long non-coding RNA (lncRNA) ROLLCSC transfers metastatic capacity from LUAD stem cells to non-stem cells.

Through extensive molecular experiments and multi-omics analyses, the researchers discovered a highly intricate positive feedback loop driving EV uptake. They demonstrated that the GTPase protein CDC42 facilitates the encapsulation of ROLLCSC into LUAD stem cell-derived EVs. Once internalized by recipient lung cancer cells, ROLLCSC is stabilized through FTO-mediated m6A demethylation and subsequently recognized by the reader protein IGF2BP2. This enhanced stability allows ROLLCSC to profoundly reshape the cellular lipid metabolism of the recipient cells.

Specifically, ROLLCSC acts as a scaffold to facilitate the interaction between the E3 ubiquitin ligase ELOC and ACSL4, thereby accelerating the degradation of ACSL4. Since ACSL4 is a critical promoter of lipid peroxidation, its degradation significantly suppresses cellular susceptibility to ferroptosis. Furthermore, ROLLCSC functions as a competing endogenous RNA (ceRNA) targeting miR-5623-3p to upregulate SLC25A11, which improves intra-mitochondrial glutathione (GSH) transport to further counteract oxidative stress.

Remarkably, in vivo orthotopic lung metastasis models confirmed that inhibiting this ROLLCSC-mediated signaling axis—such as through ACSL4 overexpression or ELOC knockdown—significantly restored ferroptosis sensitivity and sharply reduced metastatic tumor foci in the lungs. Clinical data corroborated these findings, revealing that elevated ROLLCSC, CDC42, and SLC25A11 expression levels strongly correlate with advanced tumor progression and poor overall survival in LUAD patients.

While these collective data robustly highlight the critical influence of EV-mediated lipid metabolic reprogramming in driving tumor aggressiveness, additional studies are necessary to confirm the efficacy of ROLLCSC-targeted therapies in broader clinical settings.

In conclusion, disrupting the EV-delivered ROLLCSC signaling network offers a dual-action strategy, simultaneously enhancing ferroptosis and inhibiting metabolic-driven metastasis. This profound finding positions specific inhibitors of ROLLCSC and its downstream metabolic targets as compelling candidates for next-generation lung adenocarcinoma therapies.

Reference
Title of Original Paper: Intratumoral microenvironment remodeling by lncRNA ROLLCSC enhances lung adenocarcinoma progression

Journal: Genes & Diseases

Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101788

Funding Information:

1. The National Natural Science Fund (Grant No. 82073277 and No. 82173247)
2. Science and Technology Research Program of Chongqing Municipal Education Commission (Grant No. KJQN 202200456)
3. Project of Chongqing Natural Science Foundation Innovation and Development Fund (Municipal Education Commission) (Grant No. CSTB2022NS CQ-LZX0023)
4. The Natural Science Fund of Chongqing (Grant No. CSTB2024NSCQ-MSX0282)

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4
Impact Factor: 9.4

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #